| Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized … S Rögnvaldsson, TJ Love, S Thorsteinsdottir, ER Reed, JÞ Óskarsson, ... Blood Cancer Journal 11 (5), 94, 2021 | 92 | 2021 |
| Prevalence of smoldering multiple myeloma based on nationwide screening S Thorsteinsdóttir, GK Gíslason, T Aspelund, S Rögnvaldsson, ... Nature medicine 29 (2), 467-472, 2023 | 48 | 2023 |
| Bromotryptamine and Imidazole Alkaloids with Anti-inflammatory Activity from the Bryozoan Flustra foliacea X Di, S Wang, JT Oskarsson, C Rouger, D Tasdemir, I Hardardottir, ... Journal of Natural Products 83 (10), 2854-2866, 2020 | 29 | 2020 |
| Screening for monoclonal gammopathy of undetermined significance: a population-based randomized clinical trial. First results from the Iceland Screens, Treats, or Prevents … SY Kristinsson, S Rögnvaldsson, S Thorsteinsdottir, ER Reed, ... Blood 138, 156, 2021 | 21 | 2021 |
| Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: an international harmonized approach for data analysis KT Soh, N Came, GE Otteson, D Jevremovic, M Shi, H Olteanu, A Natoni, ... Cytometry Part B: Clinical Cytometry 102 (2), 88-106, 2022 | 16 | 2022 |
| Lipophilic fractions from the marine sponge Halichondria sitiens decrease secretion of pro-inflammatory cytokines by dendritic cells and decrease their ability to induce a Th1 … X Di, JT Oskarsson, S Omarsdottir, J Freysdottir, I Hardardottir Pharmaceutical biology 55 (1), 2116-2122, 2017 | 13 | 2017 |
| Correction: Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and … S Rögnvaldsson, TJ Love, S Thorsteinsdottir, ER Reed, JÞ Óskarsson, ... Blood Cancer Journal 13 (1), 39, 2023 | 11 | 2023 |
| Prevalence of smoldering multiple myeloma: results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study S Thorsteinsdottir, GK Gislason, T Aspelund, S Rögnvaldsson, ... Blood 138 (Supplement 1), 151-151, 2021 | 10 | 2021 |
| Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index JÞ Óskarsson, S Rögnvaldsson, S Thorsteinsdottir, T Aspelund, ... Blood cancer journal 13 (1), 177, 2023 | 4 | 2023 |
| Transient M-proteins: epidemiology, causes, and the impact of mass spectrometry: the Istopmm study R Palmason, O Berlanga, JK Sigurdsson, S Rögnvaldsson, ... Blood 140 (Supplement 1), 2338-2340, 2022 | 3 | 2022 |
| Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study O Pérez-Escurza, J Flores-Montero, JÞ Óskarsson, L Sanoja-Flores, ... Blood Cancer Journal 13 (1), 182, 2023 | 2 | 2023 |
| Monitoring of circulating tumor plasma cells in patients with precursor conditions of multiple myeloma: Data from the Prospective Iceland Screens, Treats, or Prevents Multiple … JÞ Óskarsson, I Petursdottir, S Rögnvaldsson, S Thorsteinsdottir, ... Blood 138, 2645, 2021 | 2 | 2021 |
| The early benefits and psychological effects of screening for monoclonal gammopathy of undetermined significance: results of the istopmm study S Rögnvaldsson, S Thorsteinsdottir, J Oskarsson, E Eythorsson, ... Blood 142, 214, 2023 | 1 | 2023 |
| Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors by Next-Generation Flow Cytometry: Data from the Iceland Screens, Treats, or … JÞ Óskarsson, S Rögnvaldsson, S Thorsteinsdóttir, GK Hakonardottir, ... Blood 140 (Supplement 1), 7166-7167, 2022 | 1 | 2022 |
| Monoclonal gammopathy of undetermined significance and the risk of thrombotic events: Results from iStopMM, a prospective population‐based screening study S Rögnvaldsson, A Gasparini, S Thorsteinsdottir, I Sverrisdottir, ... British Journal of Haematology, 2024 | | 2024 |
| Approaching Hypercalcemia in Monoclonal Gammopathy of Undetermined Significance: Insights from the iStopMM screening study ÁH Jónsdóttir, HÁ Sigurjónsdóttir, S Thorsteinsdottir, TE Long, ... Blood, 2024 | | 2024 |
| The significance of free light-chain ratio in light-chain monoclonal gammopathy of undetermined significance: a flow cytometry sub-study of the iStopMM screening study JÞ Óskarsson, S Rögnvaldsson, S Thorsteinsdottir, TE Long, A Ólafsson, ... Blood Cancer Journal 14 (1), 221, 2024 | | 2024 |
| Differential Detection of Clonal Bone Marrow Plasma Cells in IgA Vs. IgG Monoclonal Gammopathy of Undetermined Significance and Its Association with Disease Progression JT Oskarsson, S Rögnvaldsson, S Thorsteinsdottir, A Olafsson, ... Blood 144, 1015, 2024 | | 2024 |
| Monoclonal gammopathy of undetermined significance with multiple paraproteins: A population‐based screening study S Rögnvaldsson, JÞ Óskarsson, S Thorsteinsdóttir, M Hultcrantz, ... HemaSphere 8 (11), e70046, 2024 | | 2024 |
| Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and Sweden S Rögnvaldsson, S Thorsteinsdóttir, E Syriopoulou, I Sverrisdottir, ... Haematologica 109 (7), 2250, 2024 | | 2024 |
